Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31506855 | 1.00 | CYP46A1 (0.53) | CYP46A1NR4A2TDP1ALDH1A1HPGD | |
| SCHEMBL1277539 | 0.82 | CA12 (0.44) | ALDH1A1HPGDKDM4ECA12CA1 | |
| SCHEMBL1206018 | 0.82 | CYP46A1 (0.57) | CYP46A1NR4A2TDP1ALDH1A1HPGD | |
| SCHEMBL14048740 | 0.81 | TSHR (0.53) | TDP1ALDH1A1HPGDKDM4ECA12 | |
| SCHEMBL166743 | 0.81 | CA12 (0.67) | ALDH1A1HPGDKDM4ECA12CA1 | |
| SCHEMBL27707943 | 0.81 | KDM4E (0.58) | TDP1ALDH1A1HPGDKDM4ECA12 | |
| SCHEMBL2982404 | 0.80 | CISD2 (0.40) | CYP46A1CISD2CA12CA1CA2 | |
| SCHEMBL1170022 | 0.80 | CYP46A1 (0.56) | CYP46A1NR4A2TDP1HPGDCISD2 | |
| SCHEMBL30364839 | 0.80 | CYP46A1 (0.56) | CYP46A1NR4A2TDP1HPGDCISD2 | |
| SCHEMBL13352642 | 0.79 | CA12 (0.46) | ALDH1A1HPGDKDM4ECA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297135-A1 | PROCESS FOR THE PREPARATION OF AN OREXIN RECEPTOR ANTAGONIST | Merck Sharp & Dohme Corp. (US) | 2011-03-23 | — | — | EP | claimed |
| WO-2009143033-A1 | PROCESS FOR THE PREPARATION OF AN OREXIN RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 2009-11-26 | — | — | WO | claimed |
| CN-122010922-A | Benzoxazole compounds, pharmaceutical compositions containing same and uses thereof | 株洲千金药业股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12570651-B2 | Quinazoline-2,4-dione derivatives as PARP inhibitors | Suzhou Four Health Pharmaceuticals Co., Ltd. (CN) | 2026-03-10 | — | — | US | disclosed |
| EP-4665495-A1 | DEVELOPMENT OF LIGANDS FOR METALS AND METAL-CATALYZED REACTIONS | Indian Institute of Technology Bombay (IN) | 2025-12-24 | — | — | EP | disclosed |
| US-20250224675-A1 | RESIST COMPOSITION, RESIST PATTERN FORMATION METHOD, AND COMPOUND | TOKYO OHKA KOGYO CO., LTD. (JP) | 2025-07-10 | — | — | US | disclosed |
| CN-119912402-A | FTO inhibitor and preparation method and application thereof | 中国科学院上海药物研究所 | 2025-05-02 | — | — | CN | disclosed |
| CN-113939288-B | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-3676261-B1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LTD (GB) | 2024-12-18 | — | — | EP | disclosed |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-09-12 | — | — | US | disclosed |
| EP-1586565-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | Pharmacia Corporation (US) | 2005-10-19 | — | — | EP | disclosed |
| US-6908919-B2 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-06-21 | — | — | US | disclosed |
| EP-1202975-B1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORP (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20050043313-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
| US-20040102448-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-05-27 | — | — | US | disclosed |
| US-20040006230-A1 | Useful as inhibitors of serine proteases; for therapy and prophylaxis of thrombotic conditions including coronary artery and cerebrovascular diseases | PHARMACIA CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6664255-B1 | 1-alkylamido-3-amino substituted; inhibiting serine proteases | PHARMACIA CORPORATION | 2003-12-16 | — | — | US | disclosed |
| EP-1202975-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2000069834-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102448-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, TFPI2 | CYP46A1 628/4885NR4A2 3213/4885TDP1 1921/4885 |
| US-20050043313-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | TFPI, TFPI2, PLAT | CYP46A1 632/4885NR4A2 3121/4885TDP1 2092/4885 |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | CYP46A1 965/4885NR4A2 179/4885TDP1 4585/4885 |
| US-20250224675-A1 | RESIST COMPOSITION, RESIST PATTERN FORMATION METHOD, AND COMPOUND | RER1, RARA, RARG | CYP46A1 2971/4885NR4A2 292/4885TDP1 3036/4885 |
| US-20040006230-A1 | Useful as inhibitors of serine proteases; for therapy and prophylaxis of thrombotic conditions including coronary artery and cerebrovascular diseases | PRSS1, SERPINC1, SERPINE1 | CYP46A1 728/4885NR4A2 4636/4885TDP1 1179/4885 |
| US-12570651-B2 | Quinazoline-2,4-dione derivatives as PARP inhibitors | PARP1, PARP3, PARP2 | CYP46A1 4724/4885NR4A2 3709/4885TDP1 121/4885 |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | CYP46A1 1768/4885NR4A2 344/4885TDP1 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.